Cross-Sectional Iloperidone IVGTT



Status:Completed
Conditions:Schizophrenia, Psychiatric, Endocrine, Endocrine
Therapuetic Areas:Endocrinology, Psychiatry / Psychology
Healthy:No
Age Range:18 - 65
Updated:3/14/2019
Start Date:October 2012
End Date:May 2016

Use our guide to learn which trials are right for you!

Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)

This study aims to utilize state of the art procedures such as the frequently sampled
intravenous glucose tolerance test (FSIVGTT), Bergman's Minimal Model Analysis, lipoprotein
analysis, and DEXA scans to demonstrate that a newer agent, iloperidone, is devoid of the
metabolic abnormalities associated with other atypical antipsychotic treatments, namely
olanzapine and risperidone, and offers an advantage over these other agents.

This one-month research study examines how Fanapt® (iloperidone), Zyprexa® (olanzapine), or
Risperdal® (risperidone) affect glucose metabolism in patients with schizophrenia,
schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS,
delusional disorder or paranoid disorder. This study requires 3 research visits and includes
a physical exam, medical history, vitals, an EKG, cognitive testing, psychological rating
scales, a DEXA scan, a nutritional assessment, a 3-hour intravenous glucose tolerance test
(IVGTT) and a fasting blood draw.

Inclusion Criteria:

1. Male/Female ages 18-65 years

2. Capacity to provide informed consent

3. BMI between 20 and 30 kg/m²

4. Diagnosis of a serious mental illness, including schizophrenia, any subtype;
schizoaffective disorder, any subtype; major depressive disorder, bipolar disorder,
psychosis NOS, delusional disorder and paranoid disorder

5. Treatment with iloperidone, risperidone, or olanzapine for at least 6 months

6. Stable dose of antipsychotic agent for at least one month

7. Well established compliance with out-patient medications and clinically stable

8. Female subjects will be eligible to participate in the study if they are of
non-childbearing potential or of child-bearing potential and willing to practice
appropriate birth control methods (complete abstinence from sexual intercourse, female
sterilization, sterilization of male partner, implants of levonorgestrel, injectable
progestogen, oral contraceptives, intrauterine devices, or double barrier methods of
contraception using spermicide with either a condom or diaphragm) during the study.

Exclusion Criteria:

1. Inability to provide informed consent

2. Current substance abuse

3. Psychiatrically unstable and/or hospitalized in the past month

4. History of significant and untreated medical illness including severe cardiovascular,
hepatic, renal, or untreated thyroid disease; hepatitis; or HIV

5. Current insulin treatment for diabetes

6. Currently taking the following medications: birth control pills containing norgestrol,
steroids, thiazide diuretics, or treatment with agents that induce weight loss

7. Intentions of donating blood during or within 30 days of completion of the study.

8. Use of valproate or carbamazepine within four weeks of the study

9. History of immunosuppression

10. Current or recent radiation or chemotherapy treatment for cancer

11. Pregnancy or breastfeeding
We found this trial at
1
site
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials